Navigation Links
Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
Date:4/29/2008

PARIS, April 30 /PRNewswire-FirstCall/ -- ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, announces changes in its Supervisory Board.

Following the annual shareholders' meeting of the Company, that was held on April 25th, 2008, Mr. Edmund Olivier de Vezin's appointment as member of the Supervisory Board, and as vice-chairman of the Board, expired as he has reached the age limit defined in the Company by-laws. The Supervisory Board then appointed Mr. Patrick Langlois, who had just been re-elected during the shareholders'meeting, as vice-chairman of the Board.

ExonHit Therapeutics'shareholders have also elected Mr. Frederic Desdouits, Ph.D. as member of the Supervisory Board.

Mr. Desdouits has been a partner with Bionest Partners, a consultancy firm focused on Life Sciences since 2005. Before joining Bionest, Frederic was head of Pharma Equity Research and a partner at Exane BNP Paribas. He also was head of a research team at GlaxoWellcome, and a Scientific Consultant for Hoechst and Guest Investigator at the Rockefeller University, New York, where he worked on Alzheimer's Disease. Frederic holds a Ph.D. from the College de France in collaboration with Rhone-Poulenc. He holds an MSc in pharmacology and is a graduate of Ecole Polytechnique. He is also a member of the ACIIA.

"I am delighted to join the Supervisory Board of ExonHit and look forward to contributing to the analysis of strategic opportunities for the growth of ExonHit, based on my experience as a scientist, finance person and consultant" said Mr. Desdouits.

The Supervisory Board is chaired by Mr. Laurent Condomine, and Mr. Patrick Langlois is vice-chairman. The other Board members are Ms. Deborah Smeltzer, Mr. Christophe Jean, Mr. Michel Picot and Mr. Frederic Desdouits.

"We are very pleased to have Frederic Desdouits sitting on the Supervisory Board of ExonHit Therapeutics. His professional background, his knowledge of shareholder expectations and of the competitive environment of the Life Science industry will be a strategic asset to ExonHit" said Philippe Rousseau, Chairman of the Management Board of ExonHit. "Also, we are very grateful to Mr. Edmund Olivier de Vezin for his valuable advice, his unwavering support and his active participation in ExonHit's development during the ten years he has spent with the Company's Board. Mr. Olivier de Vezin, who represents the Oxford BioSceince Partners funds, invested in ExonHit since its inception and remains ExonHit's first shareholder. We are very happy that Mr Olivier de Vezin continues to support with confidence the Company development through the funds he manages."

About ExonHit Therapeutics

http://www.exonhit.com

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArrayTM family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers and develops its own projects for the detection of other chronic diseases such as Alzheimer' disease or atherosclerosis.

In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.

Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005.

Contacts

ExonHit Therapeutics

Philippe Rousseau, C.E.O.

Tel: +33-1-58-05-47-00

philippe.rousseau@exonhit.com

This press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.


'/>"/>
SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer
2. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
3. Danong Chen appointed CEO of Theranostics Health
4. eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008
5. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
6. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
7. Mr. Richard Decker Appointed Technical Director of Edgewood Chemical Biological Center
8. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
9. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
10. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
11. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... BOSTON (PRWEB) , ... October 12, 2017 , ... ... name for two-dimensional representations of a complex biological network, a depiction of a ... a big mess,” said Dmitry Korkin, PhD, associate professor of computer science at ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract ... to improve patient outcomes and quality of life, will now be offering its ... attributed to new regulatory requirements for all new drug products, including the finalization ...
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
(Date:10/11/2017)... Austin, TX (PRWEB) , ... October 11, 2017 ... ... in August compared the implantation and pregnancy rates in frozen and fresh ... the contribution of progesterone and maternal age to IVF success. , After comparing ...
Breaking Biology Technology:
(Date:8/15/2017)... Va. , Aug. 15 2017   ivWatch LLC , ... of intravenous (IV) therapy, today announced receipt of its ISO 13485 ... developed by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the ... "This is ...
(Date:6/23/2017)... and ITHACA, N.Y. , ... and Cornell University, a leader in dairy research, today ... bioinformatics designed to help reduce the chances that the ... the onset of this dairy project, Cornell University has ... for Sequencing the Food Supply Chain, a food safety ...
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
Breaking Biology News(10 mins):